Ubs Asset Management Americas Inc Intellia Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 521,706 shares of NTLA stock, worth $6.52 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
521,706
Previous 483,185
7.97%
Holding current value
$6.52 Million
Previous $5.63 Million
34.16%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding NTLA
# of Institutions
337Shares Held
98.3MCall Options Held
784KPut Options Held
713K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$163 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$134 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$120 Million0.0% of portfolio
-
State Street Corp Boston, MA4.51MShares$56.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.8MShares$47.5 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $950M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...